# Closed System Drug Transfer Device Market

> Closed System Drug Transfer Device Market Research Report By Type (Membrane-to-Membrane Systems, Needleless Systems), By Component (Vial Access Devices, Syringe Safety Devices, Accessories, Bag/Line Access Devices), By Closing Mechanism (Push to Turn System, Color-to-Color Alignment System, Luer Lock Systems, Click to Lock Systems), By Technology (Compartmentalize Devices, Diaphragm-Based Devices, Air Filtration Devices), By End Users (Hospitals & Clinics, Specialty Centers, Others) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Industry Forecast to 2035.

- **Forecast Period:** 2025-2035
- **CAGR:** 13.6%
- **2025:** USD 1.52 Billion
- **2035:** USD 5.42 Billion
- **Key Players:** ICU Medical, Equashield, B. Braun, Simplivia Healthcare, Corvida Medical, Teva Pharmaceutical, JMS Co., Ltd, Yukon Medical

**Report ID:** MRFR/HC/6264-CR · **Pages:** 146 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** July 16, 2026

**URL:** https://www.marketresearchfuture.com/reports/closed-system-drug-transfer-device-market-7733

---

## Market Summary

As per Market Research Future analysis, the Closed System Drug Transfer Device Market was estimated at 1.2 USD Billion in 2024. The Closed System Drug Transfer Device industry is projected to grow from USD 1.322 Billion in 2025 to USD 3.483 Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 10.1% during the forecast period 2025 - 2035

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Stricter occupational-exposure regulations | 25–30% | North America, Europe | Short-term (≤2 yr) | [1] |
| Rising global chemotherapy volumes | 20–25% | Global | Long-term (≥4 yr) | [5] |
| Expansion of biologic and biosimilar pipelines | 15–18% | North America, Europe, APAC | Medium-term (2–4 yr) | [6] |
| Integration with robotic compounding systems | 10–12% | North America, Europe | Medium-term (2–4 yr) | [7] |
| Hospital accreditation and quality-score linkage | 8–10% | North America | Short-term (≤2 yr) | [8] |
| National cancer-control plan rollouts in emerging economies | 8–10% | APAC, South America, MEA | Long-term (≥4 yr) | [9] |
| Insurance and GPO reimbursement pathway creation | 5–7% | North America | Short-term (≤2 yr) | [10] |

### Stricter Occupational-Exposure Regulations

Regulatory pressure is the primary driver for the Closed System Drug Transfer Device (CSTD) market. In the United States, USP General Chapter <800> provides rigorous standards for handling hazardous drugs to protect healthcare workers and the environment. While enforcement varies, non-compliance can lead to significant financial penalties imposed by state pharmacy boards and regulatory agencies to ensure workplace safety protocols are maintained.

### Rising Global Chemotherapy Administration Volumes

The World Health Organization reports that approximately 20.6 million people are diagnosed with cancer annually. Projections indicate that the number of new cases could rise to nearly 35 million annually by 2050. This surge, driven by aging populations and environmental factors, necessitates a higher frequency of intravenous chemotherapy treatments, directly increasing the volume of required closed-system drug transfers per patient.

### Biologic and Biosimilar Pipeline Expansion

The pharmaceutical pipeline is shifting toward biologics and biosimilars, which require precise containment during preparation. In 2024 alone, the U.S. FDA approved 19 biosimilar products across various therapeutic areas. As these complex treatments become more accessible to the growing patient population, the demand for standardized, safe drug transfer technologies grows proportionally to ensure consistent containment across all clinical settings.

### Robotic Compounding System Integration

High-throughput cancer centers are increasingly integrating robotic compounding suites to enhance safety and efficiency. These systems utilize advanced automation to minimize human contact with hazardous agents. By embedding closed-transfer architecture directly into the workflow, these solutions significantly reduce preparation errors and exposure incidents. Consequently, facilities are adopting these systems as critical infrastructure to support long-term, scalable oncology care operations.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Negative Impact | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| High per-unit cost and budget constraints | –15 to –18% | Emerging economies | Long-term (≥4 yr) | [11] |
| Training burden and workflow disruption | –10 to –12% | Global | Short-term (≤2 yr) | [12] |
| Proprietary connector lock-in | –8 to –10% | North America, Europe | Medium-term (2–4 yr) | [13] |
| Limited clinical evidence in non-oncology settings | –5 to –7% | Global | Medium-term (2–4 yr) | [14] |
| Waste-stream management complexities | –3 to –5% | Europe | Short-term (≤2 yr) | [15] |

### High Per-Unit Cost and Budget Constraints

Adoption of closed-system transfer devices (CSTDs) is frequently hindered by cost premiums that can exceed conventional supplies by significant margins. In many nations, public health spending remains constrained; for instance, government expenditure on health often struggles to meet national policy targets, such as the 2.5% of GDP threshold. Consequently, hospitals managing finite budgets—where capital expenditure may account for only 13% of total health spending—often prioritize essential services, delaying the adoption of mandated safety technologies.

### Training Burden and Workflow Disruption

Transitioning to closed-system workflows requires comprehensive staff training, which is complicated by chronic global workforce shortages. With a projected global shortage of 11 million health workers by 2030, healthcare facilities face immense pressure to maintain throughput. Research indicates that while well-designed training is critical for performance, the additional time required for system adaptation can temporarily impact productivity in environments already operating with 30–50% staff shortages relative to international benchmarks.

### Proprietary Connector Lock-In

The market remains fragmented by proprietary connector designs that prevent interoperability between different manufacturers' systems. Although international standards like ISO 80369 have been established to standardize small-bore connectors and improve patient safety, the implementation of these voluntary frameworks is a gradual process. Until universal specifications are fully adopted, hospitals remain tethered to specific vendor ecosystems, limiting competitive procurement and increasing long-term operational costs.

## Opportunities

## Closed System Drug Transfer Device Market Opportunities

### Emerging-Market Regulatory Harmonization

As countries in Southeast Asia and sub-Saharan Africa develop formal hazardous-drug handling regulations, a window of opportunity is opening for manufacturers willing to offer lower-cost, region-adapted kits. India's Central Drugs Standard Control Organisation is drafting safe-handling guidelines expected to take effect by 2027, potentially unlocking a USD 120 million incremental opportunity for the Closed System Drug Transfer Device Market in the subcontinent alone [[9]](https://nhc.gov.cn).

### Subscription and Service-Based Revenue Models

Providers that bundle devices with environmental monitoring, wipe-testing analytics, and compliance dashboards are commanding 25–35% price premiums over hardware-only competitors. This shift toward recurring-revenue models transforms a transactional consumables business into a multi-year service relationship, improving vendor margin stability and deepening hospital loyalty.

### Expansion into Non-Oncology Hazardous-Drug Applications

While oncology dominates current demand, there is growing recognition of reproductive toxicity and other health risks associated with non-oncology hazardous drugs. The 2024 NIOSH update to the hazardous drug list, which now comprises 236 drugs, reinforces regulatory intent to expand safety mandates. This broadening scope increases the total addressable market beyond traditional cancer-focused pharmacy settings

### Digital Twin and Data Monetization Platforms

Smart devices integrated with RFID or NFC technology can log transfer events in real time, creating valuable datasets for documentation, compliance, and workflow optimization. Aggregating this information enables benchmarking services that assist healthcare facilities in improving operational efficiency. This creates a new revenue layer, allowing manufacturers to monetize the digital infrastructure while providing actionable performance insights to their customers.

### Contract Pharmacy and Centralized Compounding Growth

The rise of centralized compounding centers, particularly 503B outsourcing facilities, creates high-volume environments ideally suited for standardized closed-system adoption. With the U.S. 503B compounding market projected to reach approximately 2.61 billion USD by 2035, these facilities are critical in managing national drug shortages and supply continuity. Their standardized, large-scale operations necessitate robust, reliable closed-transfer solutions for all sterile preparations.

## Future Outlook

## Closed System Drug Transfer Device Market Future Outlook

### AI-Enabled Pharmacy Automation

Pharmacy automation is increasingly integrating artificial intelligence to enhance the precision and safety of hazardous drug compounding. By automating dose verification and labeling, systems reduce the potential for human error and optimize throughput in high-volume settings. As healthcare systems strive for greater efficiency to meet the needs of the projected 35 million annual cancer cases by 2050, hospitals are prioritizing technology that integrates seamlessly with existing clinical software to support reproducible, safe medication preparation workflows.

### Sustainability and Circular-Economy Pressures

Healthcare waste remains a critical environmental concern, with approximately 15% of all waste generated by healthcare activities classified as hazardous—potentially infectious, toxic, or radioactive. Regulatory focus is shifting toward sustainable waste management and circular-economy principles to mitigate this environmental impact. Facilities are increasingly adopting energy-efficient technologies and improved recycling protocols for the remaining 85% of non-hazardous medical waste.

### Personalized Medicine and Small-Batch Compounding

Precision oncology is driving a fundamental shift toward personalized treatment. Clinical data indicate that biomarker-based personalized therapy can achieve response rates exceeding 30%, compared to roughly 5% in non-personalized approaches. This trend necessitates increased flexibility in pharmacy operations to accommodate frequent, small-batch compounding of tailored dosages. Modular device designs are becoming essential to manage these complex, patient-specific protocols efficiently and safely.

### Global Regulatory Convergence

Regulatory bodies are working toward harmonized quality standards to ensure consistency across pharmaceutical manufacturing and handling. Organizations like the Pharmaceutical Inspection Co-operation Scheme (PIC/S), which expanded to 57 participating authorities as of January 2026, actively promote the alignment of Good Manufacturing Practice (GMP) guidelines. These efforts focus on institutional cooperation and quality systems to ensure safety and quality oversight in clinical drug preparation.

## Segment Insights

## Closed System Drug Transfer Device Market Segmentation

### By System Type

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Needle-Less Systems | 68% share (2025) | Sharps-injury elimination mandates |
| Membrane-to-Membrane Systems | 15.1% CAGR (2026–2035) | High-throughput compounding suitability |

Needle-less systems dominate the Closed System Drug Transfer Device Market because they address two risk vectors simultaneously—drug vapor containment and needlestick prevention. Hospitals subject to OSHA's Bloodborne Pathogens Standard strongly prefer needle-free architectures for both pharmacist safety and regulatory simplicity. Membrane-to-membrane systems, though holding a smaller base, are gaining share in centralized compounding pharmacies where high daily preparation volumes justify the slightly longer setup time in exchange for superior airtight sealing performance.

### By Closing Mechanism

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Luer-Lock Systems | 41% share (2025) | Universal syringe compatibility |
| Push-to-Turn Systems | 16.8% CAGR (2026–2035) | Intuitive single-hand operation |
| Color-to-Color Alignment Systems | USD 0.28 Billion (2025) | Error-reduction visual cues |

Luer-Lock devices command the largest share of the Closed System Drug Transfer Device Market within this dimension because they connect seamlessly with the installed base of standard syringes already present in virtually every hospital. Push-to-turn systems are the fastest-growing mechanism, favored by pharmacy technicians for their ergonomic one-handed activation that reduces fatigue during extended compounding shifts.

### By Component

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Vial Access Devices | 50% share (2025) | Required for every closed-transfer event |
| Syringe Safety Devices | 15.1% CAGR (2026–2035) | Needlestick prevention compliance |
| Bag Access Devices | USD 0.22 Billion (2025) | IV-bag preparation growth |

Vial access devices anchor the component mix because they constitute the mandatory first step in any closed transfer. Their replacement frequency—typically one device per vial—creates a consumable-driven revenue stream that scales linearly with treatment volumes across the Closed System Drug Transfer Device Market.

### By Technology

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Diaphragm-Based Devices | 61% share (2025) | Proven vapor containment efficacy |
| Compartmentalized Devices | 15.4% CAGR (2026–2035) | Multi-drug handling flexibility |

Diaphragm-based technology leads the Closed System Drug Transfer Device Market due to its well-documented containment efficacy validated through NIOSH and ASTM testing protocols. Compartmentalized devices are accelerating as pharmacy operations handle broader drug portfolios requiring segregated compartments for multi-agent regimens.

### By End User

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Hospitals | 79% share (2025) | Primary site of chemotherapy administration |
| Oncology Centers | 15.1% CAGR (2026–2035) | Specialized high-volume compounding |
| Others (Retail, Home Infusion) | USD 0.05 Billion (2025) | Home-infusion service expansion |

Hospitals represent the overwhelming majority of demand in the Closed System Drug Transfer Device Market, reflecting their role as the principal setting for hazardous-drug preparation and administration. Oncology centers are the fastest-growing end-user category as stand-alone cancer treatment facilities proliferate, particularly in suburban and semi-urban areas of the United States and Western Europe.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric | Primary Investment Themes |
| --- | --- | --- |
| North America | 46.0% share (2025) | USP <800> enforcement, GPO contracting |
| Europe | USD 0.37 Billion (2025) | EU Directive 2004/37/EC compliance |
| Asia-Pacific | 16.0% CAGR (2026–2035) | National cancer plans, biosimilar uptake |
| South America | USD 0.08 Billion (2025) | Public-hospital modernization |
| Middle East & Africa | 12.8% CAGR (2026–2035) | Gulf state healthcare investment |
| Total | USD 1.52 Billion (2025) | — |

The Closed System Drug Transfer Device Market exhibits pronounced regional asymmetry, with mature markets in North America and Europe accounting for the bulk of installed capacity. At the same time, Asia-Pacific and Latin America drive the highest incremental growth.

### North America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| United States | 78% of regional share | USP <800> mandate, private payer coverage |
| Canada | 14.2% CAGR (2026–2035) | Provincial pharmacy standards alignment |
| Mexico | USD 0.03 Billion (2025) | COFEPRIS regulatory modernization |

The United States remains the epicenter of the Closed System Drug Transfer Device Market in North America, with roughly 5,400 hospitals and 650 outpatient infusion centers currently using closed-system platforms. Canada is accelerating adoption as the National Association of Pharmacy Regulatory Authorities harmonizes provincial safe-handling standards, while Mexico's COFEPRIS is aligning import regulations with PAHO guidelines, opening a nascent but growing procurement channel.

### Europe

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Germany | 22% of regional share | Berufsgenossenschaft workplace rules |
| United Kingdom | 13.8% CAGR (2026–2035) | NHS pharmacy transformation program |
| France | USD 0.05 Billion (2025) | ANSM compounding regulations |
| Italy | 14.0% CAGR (2026–2035) | Regional oncology network expansion |
| Spain | 10% of regional share | National Health System procurement reform |
| Nordic Countries | 12.5% CAGR (2026–2035) | Centralized pharmacy models |
| Russia | USD 0.02 Billion (2025) | Federal oncology program |
| Rest of Europe | 18% of regional share | EU Directive compliance wave |

Europe's regulatory apparatus provides a durable demand floor for the Closed System Drug Transfer Device Market. Germany leads the region through stringent Berufsgenossenschaft occupational-health requirements, while the UK's NHS Long Term Plan has earmarked GBP 45 million for pharmacy automation and closed-system procurement between 2024 and 2029 [[2]](https://eur-lex.europa.eu).

### Asia-Pacific

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| China | 28% of regional share | Healthy China 2030 initiative |
| India | 17.5% CAGR (2026–2035) | CDSCO guidelines development |
| Japan | USD 0.06 Billion (2025) | MHLW workplace exposure standards |
| South Korea | 15.8% CAGR (2026–2035) | MOHW hospital accreditation reform |
| ASEAN | 16.2% CAGR (2026–2035) | Regional oncology center expansion |
| Rest of Asia-Pacific | 14% of regional share | Public-health infrastructure build-out |

Asia-Pacific is the fastest-growing geography in the Closed System Drug Transfer Device Market, propelled by China's Healthy China 2030 program, which has designated cancer treatment infrastructure as a priority investment area with over CNY 60 billion allocated through provincial health bureaus [[9]](https://nhc.gov.cn). India and South Korea are emerging as high-growth pockets as both countries tie hospital accreditation scores to hazardous-drug handling compliance.

### South America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Brazil | 58% of regional share | ANVISA compounding regulation |
| Argentina | 13.5% CAGR (2026–2035) | Public oncology center upgrades |
| Rest of South America | USD 0.01 Billion (2025) | PAHO guideline adoption |

Brazil dominates the South American Closed System Drug Transfer Device Market, where ANVISA's 2023 updated good-compounding-practice guidelines require closed handling for all antineoplastic preparations in facilities exceeding 500 monthly preparations [[17]](https://gov.br/anvisa).

### Middle East & Africa

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 32% of regional share | Vision 2030 healthcare expansion |
| UAE | 14.5% CAGR (2026–2035) | DHA hospital licensing standards |
| South Africa | USD 0.01 Billion (2025) | National Health Insurance rollout |
| Egypt | 13.0% CAGR (2026–2035) | New oncology center construction |
| Rest of MEA | 28% of regional share | Gulf Cooperation Council procurement |

Gulf state investment is the primary engine for the Closed System Drug Transfer Device Market in this region. Saudi Arabia's Vision 2030 healthcare pillar has committed SAR 18 billion to hospital construction and equipping, with pharmacy safety infrastructure specifically identified as a priority line item [[18]](https://vision2030.gov.sa).

## Competitive Benchmarking

## Competitive Benchmarking

The Closed System Drug Transfer Device Market exhibits moderate concentration, with the top five players collectively accounting for an estimated 55–62% of global revenue. The Herfindahl-Hirschman Index falls in the 1,200–1,500 range, indicating a market structure where a few established incumbents compete alongside a growing cohort of specialized challengers and regional entrants.

| Company | Est. Revenue Share Range | Key Offerings | Strategic Positioning |
| --- | --- | --- | --- |
| Becton, Dickinson and Company (BD) | 18–22% | PhaSeal Pro, PhaSeal Optima | Market leader; broadest hospital installed base |
| ICU Medical | 12–16% | ChemoLock, Diana's hazardous drug system | Strong GPO relationships in North America |
| Equashield | 8–11% | Equashield II Pro | Fully mechanical system; no elastomeric components |
| B. Braun | 6–9% | Cyto-Set, OnGuard | European market anchor; IV therapy integration |
| Simplivia Healthcare | 5–7% | Chemfort | Compact design for low-volume pharmacies |
| Corvida Medical | 3–5% | Corvida CSTD platform | Next-gen air-cleaning technology differentiator |
| Teva Pharmaceutical | 3–5% | Various contract supply agreements | Vertical integration with generic oncology drugs |
| JMS Co., Ltd | 2–4% | JMS CSTD kits | Asia-Pacific distribution strength |
| Yukon Medical | 2–3% | Yukon ChemoClave | Cost-competitive alternative for mid-tier hospitals |
| Caragen Ltd | 1–3% | Tevadaptor | Needle-free technology for resource-limited settings |

## Recent News & Developments

## Recent News & Developments

- EQUASHIELD(September 2025):EQUASHIELD launched CellSHIELD, a new CSTD designed to protect healthcare workers and patients by ensuring safe drug handling, preparation, and administration.
- Elcam Medical(September 2026): Elcam Medical introduced OLAV™, a closed male Luer connector featuring an automatic closure and locking collar to ensure leak-free, safe drug handling.
- Takeda(October 2026): Takeda launched HyHub and HyHub Duo in the U.S. to enable needle-free preparation of HYQVIA® infusions, reducing handling steps and exposure risks.

## Report Scope

## Closed System Drug Transfer Device Market Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global Closed System Drug Transfer Device Market |
| Study Period | 2021–2035 |
| Historical Period | 2021–2024 |
| Base Year | 2025 |
| Forecast Period | 2026–2035 |
| CAGR (2026–2035) | 13.6% |
| Market Size (2025) | USD 1.52 Billion |
| Market Size (2035) | USD 5.42 Billion |
| Fastest Growing Region | Asia-Pacific |
| Fastest Growing Segment | Push-to-Turn Systems (by closing mechanism) |
| Companies Profiled | 10 |
| Valuation Currency | USD Billion |

## Frequently Asked Questions

**Q: How should procurement teams evaluate the total cost of ownership when selecting a CSTD vendor?**
A: Total cost of ownership extends well beyond per-unit device price. Teams should factor in training hours, waste disposal fees, and multi-year contract escalation clauses to compare true lifecycle costs across vendors [12].

**Q: What interoperability risks arise when hospitals use CSTDs from multiple manufacturers simultaneously?**
A: Mixing proprietary connector types within a single pharmacy creates cross-contamination risk at handoff points. Standardizing on one platform per compounding area eliminates adapter mismatches and reduces technician error [13].

**Q: How do reusable CSTD components compare with fully disposable systems on infection-control metrics?**
A: Reusable components lower waste volume but require validated cleaning protocols between uses. Facilities without robust reprocessing infrastructure should default to single-use systems to maintain sterility assurance [15].

**Q: What role do group purchasing organizations play in shaping CSTD pricing in the United States?**
A: GPOs aggregate demand across member hospitals to negotiate volume-based discounts, typically achieving 15–25% reductions from list price. Sole-source GPO contracts increasingly tie pricing to compliance-monitoring service bundles [10].

**Q: Are there specific CSTD design considerations for home-infusion pharmacy applications?**
A: Home-infusion settings require compact, pre-assembled kits that minimize manipulation steps for non-specialist caregivers. Devices with color-coded alignment and fewer than three activation steps show the highest caregiver compliance rates [8].

**Q: How might upcoming ASTM standardization efforts affect existing CSTD patents and market structure?**
A: A universal connector standard could erode proprietary lock-in advantages held by incumbents. Smaller manufacturers with adaptable designs stand to gain market access once interoperability benchmarks are finalized [13].

**Q: What environmental certifications are emerging for sustainable CSTD packaging and disposal?**
A: The EU's proposed extended-producer-responsibility framework will require manufacturers to fund end-of-life recycling for medical plastics by 2031. Early adopters of recyclable polypropylene housings are positioning for compliance ahead of mandate deadlines [15].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/closed-system-drug-transfer-device-market-7733*